Sareum Holdings PLC (LSE:SAR) said its retail offer through the Winterflood Retail Access Platform was oversubscribed and closed early, and that it enlarged the offer to meet part of the excess demand. Together with a separate subscription, the fundraising is expected to bring in gross proceeds of about £3.34 million.

What was announced

Sareum Holdings PLC (LSE:SAR), which describes itself as a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, published the result of its retail offer on 28 October 2026. The announcement follows the company's statements of 26 October 2026, including one released at 7:01 a.m. that day, which set out the original terms of the fundraising.

The retail element was run through the Winterflood Retail Access Platform (WRAP), which allows private investors to take part in placings and subscriptions through participating intermediaries. Sareum said the WRAP retail offer "was oversubscribed and closed early". The company added that it had decided to increase the size of the offer to partially accommodate some of the excess demand. It did not say how large the excess demand was or what the original target for the retail tranche had been.

The numbers

According to the announcement, the retail offer raised gross proceeds of approximately £150,000 through the issue of 1,071,422 new ordinary shares. Alongside this, the company is issuing 22,807,143 subscription shares under the separate subscription announced earlier in the week.

Sareum (LSE:SAR) said the combined gross proceeds of the subscription and the retail offer amount to approximately £3.34 million. The 28 October announcement does not restate the issue price. On the disclosed figures, dividing the retail proceeds of about £150,000 by the 1,071,422 retail shares implies a price of roughly 14 pence per share, and the combined figures produce a similar result. Readers should check the 26 October announcement for the exact price.

On the disclosed figures, the subscription and retail offer together involve 23,878,565 new ordinary shares. Most of the money therefore comes from the subscription, with the retail tranche accounting for around 4.5% of the total gross proceeds, again on the disclosed figures.

Following admission of the new shares, Sareum's issued share capital will consist of 163,604,747 ordinary shares, each carrying one vote. The company holds no shares in treasury, so this is the figure shareholders should use as the denominator when working out whether they must notify an interest, or a change in their interest, under the FCA's Disclosure Guidance and Transparency Rules. On the disclosed figures, the new shares represent about 14.6% of the enlarged share capital, which gives a sense of the dilution for shareholders who did not take part.

Timetable and use of proceeds

Application has been made for the new shares to be admitted to trading on AIM, and admission is expected to take place at 8:00 a.m. on or around 29 October 2026.

The results announcement does not set out how the money will be used, and it contains no financial results, trading update, guidance or details of any director participation. Information on the intended use of proceeds and the terms of the subscription is expected to sit in the earlier 26 October announcements, which were not part of this release.

Strand Hanson is Sareum's nominated adviser, and Winterflood ran the retail offer through WRAP. Stephen Parker, Executive Chairman, is listed as the company contact.

What to watch next

The immediate step is admission of the new shares, expected on or around 29 October. After that, investors will look for detail on how the roughly £3.34 million gross is deployed across Sareum's kinase inhibitor programmes, and for any clinical or regulatory updates the company publishes. The announcement makes no forward-looking statements on development milestones, so any timetable will need to come from future company disclosures. The gross figures are stated before fundraising costs, which the announcement does not quantify.